Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease (CKD) is characterized by a progressive decline in renal function and remains incurable, although therapeutic interventions can alleviate symptoms and slow disease progression. Uremia-associated alterations in plasma amino acid levels have been observed in CKD patients, suggesting that amino acid supplementation may benefit renal metabolism and function. AB070597, a patented formulation composed of amino acids and small peptides, has been proposed as a nutritional supplement to support renal health; however, experimental evidence for its efficacy remains limited. This study aimed to evaluate the protective effects of AB070597 on renal function and fibrosis in a mouse model of CKD.
Renal failure was induced in male C57BL/6J mice by feeding a 0.2% adenine-containing diet for six weeks. Mice were randomly assigned to three groups: control, renal failure (RF), and renal failure treated with AB070597 (RF+AB). AB070597 or vehicle (0.5% methylcellulose 400 solution) was administered orally twice daily for six weeks. Blood and kidney samples were collected after six weeks of administration. Blood urea nitrogen (BUN), plasma creatinine, and cystatin C levels were measured as markers of renal function. Kidney histopathology was assessed by Elastica–Masson staining, and the remaining cortical tubular area was quantified to evaluate renal fibrosis. Gene expression levels of Col4a1, Ctgf, Pai1, and Tissue Factor (Tf) were quantified by RT-qPCR.
In the RF group, levels of BUN, creatinine, and cystatin C were markedly increased, indicating renal dysfunction, whereas these elevations were significantly attenuated in the RF+AB group. Histologically, pronounced tubular atrophy and interstitial fibrosis were observed in RF kidneys, while AB070597 treatment preserved cortical tubular structures and significantly increased the remaining tubular area compared with the RF group. Furthermore, the mRNA expression of Col4a1, Ctgf, Pai1, and Tf was markedly upregulated in RF kidneys, suggesting activation of fibrotic and coagulation-related pathways. In contrast, AB070597 administration significantly suppressed the expression of these genes, indicating inhibition of the coagulation–PAR–TGF-β signaling crosstalk that contributes to fibrosis progression.
Administration of the amino acid and dipeptide complex AB070597 mitigated renal fibrosis and preserved renal function in an adenine-induced CKD mouse model. The coordinated downregulation of TF, CTGF, PAI-1, and collagen IV suggests that AB070597 exerts renoprotective effects by suppressing TF-driven coagulation signaling and TGF-β–mediated profibrotic responses. These findings highlight AB070597 as a potential nutritional therapeutic candidate for preventing CKD progression through inhibition of coagulation-linked fibrotic pathways.
